ADMA Biologics Inc (NASDAQ:ADMA) – Research analysts at Dawson James lowered their FY2021 earnings per share (EPS) estimates for shares of ADMA Biologics in a note issued to investors on Monday, August 12th. Dawson James analyst J. Kolbert now expects that the biotechnology company will earn $0.18 per share for the year, down from their previous forecast of $0.19. Dawson James has a “Neutral” rating and a $4.00 price target on the stock. Dawson James also issued estimates for ADMA Biologics’ FY2022 earnings at $0.78 EPS and FY2023 earnings at $1.36 EPS.
A number of other brokerages have also recently commented on ADMA. Oppenheimer set a $14.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Tuesday, June 25th. HC Wainwright set a $13.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Finally, Jefferies Financial Group started coverage on shares of ADMA Biologics in a research report on Tuesday, June 4th. They issued a “buy” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.17.
Shares of NASDAQ:ADMA opened at $3.90 on Wednesday. The stock has a market cap of $226.37 million, a PE ratio of -2.69 and a beta of 2.71. The company’s fifty day moving average is $3.73 and its 200 day moving average is $4.03. ADMA Biologics has a 52 week low of $2.08 and a 52 week high of $6.96. The company has a quick ratio of 2.39, a current ratio of 4.60 and a debt-to-equity ratio of 5.70.
ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $4.36 million. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 273.18%.
In other news, major shareholder Life Sciences Maste Perceptive acquired 4,000,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were purchased at an average price of $4.00 per share, for a total transaction of $16,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of the business’s stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $3.75, for a total transaction of $21,802,327.50. Following the completion of the transaction, the insider now owns 4,295,580 shares in the company, valued at approximately $16,108,425. The disclosure for this sale can be found here. 15.20% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in ADMA. Jane Street Group LLC increased its holdings in ADMA Biologics by 25.1% during the second quarter. Jane Street Group LLC now owns 58,374 shares of the biotechnology company’s stock valued at $226,000 after buying an additional 11,711 shares during the last quarter. Citadel Advisors LLC increased its holdings in ADMA Biologics by 96.3% during the second quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 10,887 shares during the last quarter. Jefferies Group LLC purchased a new stake in ADMA Biologics during the second quarter valued at approximately $2,961,000. Marshall Wace North America L.P. purchased a new stake in ADMA Biologics during the second quarter valued at approximately $1,128,000. Finally, Vanguard Group Inc. increased its holdings in ADMA Biologics by 47.3% during the second quarter. Vanguard Group Inc. now owns 2,448,253 shares of the biotechnology company’s stock valued at $9,474,000 after buying an additional 786,567 shares during the last quarter. Hedge funds and other institutional investors own 38.82% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
See Also: What is the Bid-Ask Spread?
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.